DCPXF (DanCann Pharma AS) Debt-to-EBITDA : 0.00 (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DCPXF DanCann Pharma AS DCPXF
20 GF Score
Price $10.00
GF Value $37.14
! 3 Warning Signs
View Full Analysis

What is DanCann Pharma AS Debt-to-EBITDA?

DanCann Pharma AS DCPXF 20 Debt-to-EBITDA is 0.00 as of Sep. 2025. GuruFocus rates DCPXF with a GF Score™ of 20/100 and a GF Value™ of $37.14. The stock has 3 warning signs investors should review.

Debt-to-EBITDA measures a company's ability to pay off its debt.

DanCann Pharma AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2025 was $0.00 Mil. DanCann Pharma AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2025 was $0.00 Mil. DanCann Pharma AS's annualized EBITDA for the quarter that ended in Sep. 2025 was $-0.61 Mil. DanCann Pharma AS's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2025 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for DanCann Pharma AS's Debt-to-EBITDA or its related term are showing as below:

DCPXF's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.67
* Ranked among companies with meaningful Debt-to-EBITDA only.

DanCann Pharma AS  (GREY:DCPXF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

DanCann Pharma AS Debt-to-EBITDA Related Terms

DanCann Pharma AS Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for DanCann Pharma AS's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DanCann Pharma AS Debt-to-EBITDA Chart

DanCann Pharma AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
Get a 7-Day Free Trial -0.03 0.00 -0.58 -0.11 0.00

DanCann Pharma AS Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DCPXF vs ZTS, UTHR, RGC: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, DanCann Pharma AS's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DanCann Pharma AS Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DanCann Pharma AS's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where DanCann Pharma AS's Debt-to-EBITDA falls into.


DCPXF
20GF Score
DanCann Pharma AS DCPXF
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DanCann Pharma AS Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

DanCann Pharma AS's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -0.7
=0.00

DanCann Pharma AS's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -0.612
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2025) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of 0.00 mean?
DanCann Pharma AS (DCPXF) has a Debt-to-EBITDA of 0.00 as of Sep. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on DanCann Pharma AS.
Is DanCann Pharma AS's Debt-to-EBITDA too high?
DanCann Pharma AS's current Debt-to-EBITDA is 0.00. Overall, DanCann Pharma AS has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does DanCann Pharma AS's Debt-to-EBITDA compare to ZTS and UTHR?
DanCann Pharma AS's Debt-to-EBITDA of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-EBITDA is 1.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.67, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on DanCann Pharma AS. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DanCann Pharma AS's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DanCann Pharma AS stock overvalued right now?
DanCann Pharma AS (DCPXF) has a current Debt-to-EBITDA of 0.00. The stock's GF Value™ is $37.14, compared to a current price of $10.00 — trading 73.1% below its estimated fair value. The current Debt-to-EBITDA is 0.00. DanCann Pharma AS's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For DanCann Pharma AS (DCPXF), the current Debt-to-EBITDA is 0.00 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DanCann Pharma AS (DCPXF) Overvalued in 2026?

Based on GuruFocus' analysis, DanCann Pharma AS stock appears to be undervalued. The current stock price of $10.00 is trading 73.1% below its estimated GF Value™ of $37.14.

Key valuation signals for DCPXF:

  • Debt-to-EBITDA: 0.00
  • GF Value™: $37.14 vs. price of $10.00 (73.1% below fair value)
  • GF Score™: 20/100 with 3 warning signs

No single metric tells the full story. See the DCPXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DanCann Pharma AS Business Description

Address Rugvaenget 5, Ansager, DNK, DK-6823
DanCann Pharma AS is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company. The company is focused on discovering, developing, manufacturing, and commercializing novel cannabinoid therapeutics for a broad range of diseases.
20GF Score

Get the complete analysis for DCPXF

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.00
Price
$37.14
GF Value